Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.10 USD

94.10
1,891,045

-0.36 (-0.38%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cardinal (CAH) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What's in Store for Cooper Companies (COO) in Q4 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

McKesson (MCK) Announces Availability of FDA-Cleared Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.

Zacks.com featured highlights Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx

by Zacks Equity Research

Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx have been highlighted in this Screen of The Week article.

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Sweta Killa headshot

5 Dividend Stocks Having Strong Growth Potential

by Sweta Killa

Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.

Maharathi Basu headshot

5 Broker-Friendly Stocks to Keep an Eye on Amid Volatility

by Maharathi Basu

We believe that stocks like Brinker International (EAT), Cardinal Health (CAH), The Andersons (ANDE), Avnet (AVT) and Group 1 Automotive (GPI) should be on an investor's watchlist.

Derek Lewis headshot

This Combination of 3 Stocks Provides Monthly Income

by Derek Lewis

Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?

3 Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome

by Zacks Equity Research

Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) strength in business raises optimism about the stock.

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)

by Zacks Equity Research

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes

by Zacks Equity Research

The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.

Should Value Investors Buy Cardinal Health (CAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?

by Zacks Equity Research

Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.

Why You Should Add Integer Holdings (ITGR) to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.